Triple

T5932432
Position Surface form Disambiguated ID Type / Status
Subject ICH Q9 Quality Risk Management E131968 entity
Predicate fullName P16 FINISHED
Object International Council for Harmonisation Guideline Q9: Quality Risk Management E131968 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: International Council for Harmonisation Guideline Q9: Quality Risk Management | Statement: [ICH Q9 Quality Risk Management, fullName, International Council for Harmonisation Guideline Q9: Quality Risk Management]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: International Council for Harmonisation Guideline Q9: Quality Risk Management
Context triple: [ICH Q9 Quality Risk Management, fullName, International Council for Harmonisation Guideline Q9: Quality Risk Management]
  • A. ICH Q9 Quality Risk Management chosen
    ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
  • B. ICH Q8 Pharmaceutical Development
    ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
  • C. ICH Q10 Pharmaceutical Quality System
    ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
  • D. ICH Q11 Development and Manufacture of Drug Substances
    ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
  • E. ICH Q3A Impurities in New Drug Substances
    ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c0085b75e88190a632f9691f9da48b completed March 22, 2026, 3:18 p.m.
NER Named-entity recognition batch_69c0389df18c81909027a9db7596f0c1 completed March 22, 2026, 6:44 p.m.
NED1 Entity disambiguation (via context triple) batch_69c108186c64819088c21e9b5408d5f1 completed March 23, 2026, 9:30 a.m.
Created at: March 22, 2026, 4 p.m.